A New Exploration Towards Aminothiazolquinolone Oximes As Potentially Multi-Targeting Antibacterial Agents: Design, Synthesis and Evaluation Acting on Microbes, DNA, HSA and Topoisomerase IV
Liang-Liang Wang,Narsaiah Battini,Rammohan R. Yadav Bheemanaboina,Mohammad Fawad Ansari,Jin-Ping Chen,Yun-Peng Xie,Gui-Xin Cai,Shao-Lin Zhang,Cheng-He Zhou
DOI: https://doi.org/10.1016/j.ejmech.2019.06.046
IF: 7.088
2019-01-01
European Journal of Medicinal Chemistry
Abstract:This work did a new exploration towards aminothiazolquinolone oximes as potentially multi-targeting antimicrobial agents. A class of novel hybrids of quinolone, aminothiazole, piperazine and oxime fragments were designed for the first time, conveniently synthesized as well as characterized by H-1 NMR, C-13 NMR and HRMS spectra. Biological activity showed that some of the synthesized compounds exhibited good antimicrobial activities in comparison with the reference drugs. Especially, O-methyl oxime derivative 10b displayed excellent inhibitory efficacy against MRSA and S. aureus 25923 with MIC values of 0.009 and 0.017 mM, respectively. Further studies indicated that the highly active compound 10b showed low toxicity toward BEAS-2B and A549 cell lines and no obvious propensity to trigger the development of bacterial resistance. Quantum chemical studies have also been conducted and rationally explained the structural features essential for activity. The preliminarily mechanism exploration revealed that compound 10b could not only exert efficient membrane permeability by interfering with the integrity of cells, bind with topoisomerase IV-DNA complex through hydrogen bonds and pi-pi stacking, but also form a steady biosupramolecular complex by intercalating into DNA to exert the efficient antibacterial activity. The supramolecular interaction between compound 10b and human serum albumin (HSA) was a static quenching, and the binding process was spontaneous, where hydrogen bonds and van der Waals force played vital roles in the supramolecular transportation of the active compound 10b by HSA. (C) 2019 Elsevier Masson SAS. All rights reserved.